Vaccine (DNA plasmid) · Immune activation, directed at HPV 16 E6 protein, HPV 16 E7 protein and HPV 18 E6 protein · developed by Inovio Pharmaceuticals
VGX-3100 is a DNA vaccine consisting of plasmids encoding HPV 16 and 18 E6 and E7 proteins, administered via intramuscular electroporation. It elicits a cytotoxic T-lymphocyte response against cervical cancer cells expressing these viral proteins. The vaccine is studied in cervical and anal intraepithelial neoplasia.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03721978 | Phase 3 | Cervical Dysplasia | Completed | INO |
| NCT03603808 | Phase 2 | Anal Intraepithelial Neoplasia | Completed | INO |
| NCT01304524 | Phase 2 | Cervical Intraepithelial Neoplasia | Completed | INO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Anal Intraepithelial NeoplasiaCervical DysplasiaCervical High Grade Squamous Intraepithelial LesionCervical Intraepithelial NeoplasiaHigh Grade Squamous Intraepithelial NeoplasiaHIV PositivityHSILHuman Papillomavirus-16 PositiveHuman Papillomavirus-18 Positive
Updated Oct 3, 2026. Something wrong or missing? Report it on the INO page.
See INO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
INO catalysts and pipeline →